Blair William & Co. IL Sells 260,409 Shares of Zoetis Inc. $ZTS

Key Points

• Blair William & Co. IL has reduced its stake in Zoetis Inc. by 13.8%, selling 260,409 shares during the second quarter, and now holds around 0.37% of the company valued at $254.49 million.
• Zoetis reported a quarterly EPS of $1.76, exceeding analysts' expectations of $1.62, with a year-over-year revenue increase of 4.2% to $2.46 billion.
• Institutional investors now own 92.80% of Zoetis stock, reflecting strong interest as companies like Nuveen and Polen Capital Management increased their holdings significantly during the first quarter.

Blair William & Co. IL decreased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 13.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,631,871 shares of the company's stock after selling 260,409 shares during the quarter. Blair William & Co. IL owned about 0.37% of Zoetis worth $254,490,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ZTS. Nuveen LLC acquired a new stake in Zoetis in the first quarter valued at $616,375,000. Mackenzie Financial Corp raised its holdings in shares of Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after purchasing an additional 1,782,110 shares during the period. Polen Capital Management LLC raised its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Amundi increased its position in Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company's stock worth $575,691,000 after buying an additional 846,909 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its position in Zoetis by 475.9% during the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company's stock worth $148,228,000 after buying an additional 743,926 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 0.6%

NYSE ZTS opened at $143.61 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55. The company has a 50 day moving average of $149.41 and a 200-day moving average of $154.74. The company has a market cap of $63.65 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 2.29 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the company earned $1.56 EPS. The company's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on ZTS shares. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Weiss Ratings reissued a "hold (c-)" rating on shares of Zoetis in a research report on Wednesday. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Argus reiterated a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.